The announcement comes with the news that the cell and gene therapy manufacturing market is now worth US$ 19.3 billion, with a compound annual growth rate (CAGR) of 29% between 2022 and 2023.

After a rocky year, bluebird bio's approval journey for a treatment for sickle cell disease looks to be back on track, with the company generating more funds by selling shares.

Can complementary approaches for off-target quantification demonstrate substantial levels in various state-of-the-art editors?

Gene knockdown – the manual reduction of a particular gene's expression in target cells – entails the modification of cellular development in young cells. CRISPR gene editing techniques enable researchers such as Pia Johansson to induce gene knockdown in target cells.

Experts from academia and industry discuss the current obstacles and opportunities for genome editing during a roundtable session at Gene Therapy Development & Manufacturing: In-Person.

Key opinion leaders from Roche and Purespring Therapeutics debate future strategies for advancing cell and gene therapeutics.

Can the cell and gene therapy field create industry consensus on a more detailed level? In this Insight Article, Jorgen Magnus, Strategic Program Lead of Cell and Gene Therapy at Bayer, highlights the promise of process mapping for reaching a harmonised approach to development and manufacturing standards.